Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nektar Therapeutics's share price for the quarter that ended in Dec. 2023 was $0.565. Nektar Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 191.38 Mil. Therefore, Nektar Therapeutics's market cap for the quarter that ended in Dec. 2023 was $108.13 Mil.
Nektar Therapeutics's quarterly market cap
increased
from Jun. 2023 ($109.36 Mil) to Sep. 2023 ($113.62 Mil) but then
declined
from Sep. 2023 ($113.62 Mil) to Dec. 2023 ($108.13 Mil).
Nektar Therapeutics's annual market cap
declined
from Dec. 2021 ($2,505.67 Mil) to Dec. 2022 ($426.15 Mil) and
declined
from Dec. 2022 ($426.15 Mil) to Dec. 2023 ($108.13 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nektar Therapeutics's Enterprise Value for Today is $102.44 Mil.
Nektar Therapeutics Market Cap Historical Data
The historical data trend for Nektar Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Nektar Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Market Cap
3,810.74
3,061.55
2,505.67
426.15
108.13
Nektar Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Market Cap
426.15
133.01
109.36
113.62
108.13
Competitive Comparison
For the Biotechnology subindustry, Nektar Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Market Cap falls into.
Nektar Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nektar Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics (NAS:NKTR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nektar Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 